Association of chromosome 8q variants with prostate cancer risk in Caucasian and Hispanic men (2009)
Beuten, Joke, Gelfond, Jonathan A. L., Martinez-Fierro, Margarita L., Weldon, Korri S., Crandall, AnaLisa C., Rojas-Martinez, Augusto, ...
Genotyping of a 615 kb region within 8q24 with 49 haplotype-tagged single-nucleotide polymorphisms (SNPs) in 2109 samples (797 cases and 1312 controls) of two ethnic/racial groups found SNPs that are...
Kristal, Alan R., Arnold, Kathryn B., Schenk, Jeannette M., Neuhouser, Marian L., Goodman, Phyllis, Penson, David F., ...
This study examined dietary risk factors for incident benign prostatic hyperplasia (BPH) in 4,770 Prostate Cancer Prevention Trial (1994–2003) placebo-arm participants who were free of BPH at...
Integrating the Predictiveness of a Marker with Its Performance as a Classifier (2008)
Pepe, Margaret S., Feng, Ziding, Huang, Ying, Longton, Gary, Prentice, Ross, Thompson, Ian M., ...
There are two popular statistical approaches to biomarker evaluation. One models the risk of disease (or disease outcome) with, for example, logistic regression. A marker is considered useful if it...
Kristal, Alan R., Schenk, Jeannette M., Song, YoonJu, Arnold, Kathryn B., Neuhouser, Marian L., Goodman, Phyllis J., ...
The authors conducted a nested case-control study of serum steroid concentrations and risk of benign prostatic hyperplasia (BPH), using data from the placebo arm of the Prostate Cancer Prevention...
CYP1B1 variants are associated with prostate cancer in non-Hispanic and Hispanic Caucasians (2008)
Beuten, Joke, Gelfond, Jonathan A.L., Byrne, John J., Balic, Ivana, Crandall, AnaLisa C., Johnson-Pais, Teresa L., ...
Cytochrome P450 1B1 (CYP1B1) is involved in the activation of many carcinogens and in the metabolism of steroid hormones. We compared allele, genotype and haplotype frequencies of six...
Etzioni, Ruth D., Ankerst, Donna P., Weiss, Noel S., Inoue, Lurdes Y. T., Thompson, Ian M.
Prostate-specific antigen velocity (PSAV) is one of the oldest concepts in PSA screening, yet today it is one of the most controversial. Publication of a wide range of studies with different designs,...
Finasteride and High-Grade Prostate Cancer in the Prostate Cancer Prevention Trial (2007)
Lucia, M. Scott, Epstein, Jonathan I., Goodman, Phyllis J., Darke, Amy K., Reuter, Victor E., Civantos, Francisco, ...
Background The Prostate Cancer Prevention Trial (PCPT) reported a decreased incidence of prostate cancer overall but an increase in the incidence of high-grade prostate cancer with finasteride...
Moinpour, Carol M., Darke, Amy K., Donaldson, Gary W., Thompson, Ian M., Langley, Connie, Ankerst, Donna Pauler, ...
Background The Prostate Cancer Prevention Trial (PCPT) was a randomized, double-blind, placebo-controlled study of the efficacy of finasteride in preventing prostate cancer in 18882 men aged 55 years...
Pinsky, Paul, Etzioni, Ruth, Howlader, Nadia, Goodman, Phyllis, Thompson, Ian M
The Prostate Cancer Prevention Trial (PCPT) recently demonstrated a significant reduction in prostate cancer incidence of about 25% among men taking finasteride compared to men taking placebo....
Pinsky, Paul, Etzioni, Ruth, Howlader, Nadia, Goodman, Phyllis, Thompson, Ian M
The Prostate Cancer Prevention Trial (PCPT) recently demonstrated a significant reduction in prostate cancer incidence of about 25% among men taking finasteride compared to men taking placebo....
Pinsky, Paul, Etzioni, Ruth, Howlader, Nadia, Goodman, Phyllis, Thompson, Ian M
The Prostate Cancer Prevention Trial (PCPT) recently demonstrated a significant reduction in prostate cancer incidence of about 25% among men taking finasteride compared to men taking placebo....
Pinsky, Paul, Etzioni, Ruth, Howlader, Nadia, Goodman, Phyllis, Thompson, Ian M
The Prostate Cancer Prevention Trial (PCPT) recently demonstrated a significant reduction in prostate cancer incidence of about 25% among men taking finasteride compared to men taking placebo....
Integrating the Predictiveness of a Marker with its Performance as a Classifier (2006)
Pepe, Margaret S., Feng, Ziding, Huang, Ying, Longton, Gary M., Prentice, Ross, Thompson, Ian M, ...
There are two popular statistical approaches to biomarker evaluation. One models the risk of disease (or disease outcome) using, for example, logistic regression. A marker is useful if it has a...
Integrating the Predictiveness of a Marker with its Performance as a Classifier (2006)
Pepe, Margaret S., Feng, Ziding, Huang, Ying, Longton, Gary M., Prentice, Ross, Thompson, Ian M, ...
There are two popular statistical approaches to biomarker evaluation. One models the risk of disease (or disease outcome) using, for example, logistic regression. A marker is useful if it has a...
Integrating the Predictiveness of a Marker with its Performance as a Classifier (2006)
Pepe, Margaret S., Feng, Ziding, Huang, Ying, Longton, Gary M., Prentice, Ross, Thompson, Ian M, ...
There are two popular statistical approaches to biomarker evaluation. One models the risk of disease (or disease outcome) using, for example, logistic regression. A marker is useful if it has a...
Integrating the Predictiveness of a Marker with its Performance as a Classifier (2006)
Pepe, Margaret S., Feng, Ziding, Huang, Ying, Longton, Gary M., Prentice, Ross, Thompson, Ian M, ...
There are two popular statistical approaches to biomarker evaluation. One models the risk of disease (or disease outcome) using, for example, logistic regression. A marker is useful if it has a...
Assessing Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial (2006)
Thompson, Ian M., Ankerst, Donna Pauler, Chi, Chen, Goodman, Phyllis J., Tangen, Catherine M., Lucia, M. Scott, ...
Background: Prostate-specific antigen (PSA) testing is the primary method used to diagnose prostate cancer in the United States. Methods to integrate other risk factors associated with prostate...
Effect of Finasteride on the Sensitivity of PSA for Detecting Prostate Cancer (2006)
Thompson, Ian M., Chi, Chen, Ankerst, Donna Pauler, Goodman, Phyllis J., Tangen, Catherine M., Lippman, Scott M., ...
Background: In the Prostate Cancer Prevention Trial (PCPT), men receiving finasteride had a 24.8% lower risk of prostate cancer than men receiving placebo but a higher risk of high-grade cancer. We...
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT) (2005)
Lippman, Scott M., Goodman, Phyllis J., Klein, Eric A., Parnes, Howard L., Thompson, Ian M., Kristal, Alan R., ...
Prostate cancer continues to be a major health threat, especially among African American men. The Selenium and Vitamin E Cancer Prevention Trial (SELECT), which opened on July 25, 2001, was planned...
Localized Prostate Cancer: Quality of Life Meets Whitmore's Legacy (2004)
Bermejo, Carlos, Kristal, Alan R., Zeliadt, Steven B., Ramsey, Scott, Thompson, Ian M.
Thompson, Ian M., Tangen, Catherine M., Tolcher, Anthony, Crawford, E. David, Eisenberger, Mario, Moinpour, Carol M.
Background: African-American men have earlier onset of prostate cancer, higher prostate-specific antigen (PSA) levels, more advanced stage at diagnosis, and higher mortality than white men. It is not...
Thompson, Ian M., Tangen, Catherine M., Tolcher, Anthony, Crawford, E. David, Eisenberger, Mario, Moinpour, Carol M.
Flare Associated with LHRH-Agonist Therapy
The most common form of hormonal treatment for prostate cancer is luteinizing hormone-releasing hormone (LHRH)-agonist therapy. During the first 1 to 3 weeks of LHRH-agonist therapy, an initial...
Flare Associated with LHRH-Agonist Therapy
The most common form of hormonal treatment for prostate cancer is luteinizing hormone-releasing hormone (LHRH)-agonist therapy. During the first 1 to 3 weeks of LHRH-agonist therapy, an initial...
Prostate-specific antigen in the early detection of prostate cancer
Thompson, Ian M., Ankerst, Donna P.
Throughout Canada, the United States and much of Europe, prostate-specific antigen (PSA) screening for prostate cancer has proliferated over the past 2 decades, leading to dramatic increases in...
Ghosh, Rita, Garcia, Gretchen E, Crosby, Katherine, Inoue, Hiroyasu, Thompson, Ian M, Troyer, Dean A, ...
We recently showed that NexrutineR, a Phellodendron amurense bark extract, suppresses proliferation of prostate cancer cell lines and tumor development in the transgenic adenocarcinoma of mouse...
CYP1B1 variants are associated with prostate cancer in non-Hispanic and Hispanic Caucasians
Beuten, Joke, Gelfond, Jonathan A.L., Byrne, John J., Balic, Ivana, Crandall, AnaLisa C., Johnson-Pais, Teresa L., ...
Cytochrome P450 1B1 (CYP1B1) is involved in the activation of many carcinogens and in the metabolism of steroid hormones. We compared allele, genotype and haplotype frequencies of six...
Role of 5 alpha-reductase inhibitors in the management of prostate cancer
Hudak, Steven J, Hernandez, Javier, Thompson, Ian M
Prostate cancer is one of the most complex and enigmatic oncologic problems in medicine. It is highly prevalent, particularly in elderly males. Unfortunately, its generally protracted and variable...